TNXP · Tonix Pharmaceuticals Holding Corp.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2025-06-11 | — | $150,000,000 | — | — | 10-Q , filed 2025-08-11 |
Cash spent on buybacks by quarter
Cash deployed each quarter, with the average price paid where the company reported it. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2025-12-31 | $13,760,000 | 10-K, filed 2026-03-12 |
| 2023-12-31 | $13,965,000 | 10-K, filed 2025-03-18 |